Eli Lilly's orforglipron beat NVO's Rybelsus in a 52-week diabetes study, showing stronger A1C and weight loss benefits.

Nvov Nordisk stock rose after a study showed Ozempic reduced the risk of heart attack, stroke and death by 23% compared with ...

Pharmaceutical giant Eli Lilly expanded its Virginia facility investment plans to $5 billion from original $2.1 billion amid ...

Eli Lilly and Company LLY announced plans to spend $5 billion to build a massive new manufacturing facility in Virginia as ...

In the latest trading session, Eli Lilly (LLY) closed at $763.57, marking a +2.06% move from the previous day. The stock's change was more than the S&P 500's daily loss of 0.13%. Meanwhile, the Dow ...

AbbVie ABBV has gained 22.5% so far this year against a decrease of 0.1% for the industry. The stock has also outperformed ...

Eli Lilly (LLY) stock in focus as the company plans to invest $5B in a new Virginia plant to boost its drug manufacturing ...

Eli Lilly and Company has recently surpassed a significant technical benchmark, reclaiming the 50-day moving average, ...

Eli Lilly shares move past the 50-day SMA as weight-loss drug data, rising sales and pipeline momentum fuel optimism.

Recently, Zacks.com users have been paying close attention to Lilly (LLY). This makes it worthwhile to examine what the stock ...

Eli Lilly and Company recently saw its stock price climb +1.51%, reaching $738.17, and surpassing the S&P 500's modest gain ...